广发量化多因子混合A（005225）基金经理为易威、李育鑫。 截至发稿，易威累计任职时间2年187天，现任基金资产总规模38.18亿元，任职期间最佳基金回报 71.19%， 任职期间最差基金回报-1.66%。 李育鑫累计任职时间2年78天，现任基金资产总规模37.93亿元，任职期间最佳基金回报102.03%， 任职 期间最差基金回报2.93%。 1月7日，谱尼测试涨5.43%，截至发稿，报14.57元/股，成交9.28亿元，换手率18.87%，总市值79.51亿 元。谱尼测试股价已经连续6天上涨，区间累计涨幅50.38%。 资料显示，谱尼测试集团股份有限公司位于北京市海淀区锦带路66号院1号楼5层101，成立日期2002年6 月10日，上市日期2020年9月16日，公司主营业务涉及检验检测、计量、认证及相关技术服务。主营业 务收入构成为：生命科学与健康环保68.89%，汽车及其他消费品19.99%，安全保障10.94%，其他业务 0.18%。 从谱尼测试十大流通股东角度 数据显示，广发基金旗下1只基金位居谱尼测试十大流通股东。广发量化多因子混合A（005225）三季 度新进十大流通股东，持有股数266.22万 ...

谱尼测试今年以来股价涨22.77%，近5个交易日涨18.43%，近20日涨10.09%，近60日涨14.53%。 今年以来谱尼测试已经1次登上龙虎榜，最近一次登上龙虎榜为12月24日，当日龙虎榜净买入6001.31万 元；买入总计1.03亿元 ，占总成交额比20.19%；卖出总计4331.91万元 ，占总成交额比8.46%。 12月26日，谱尼测试盘中上涨2.07%，截至09:50，报9.38元/股，成交1.62亿元，换手率4.86%，总市值 51.19亿元。 资金流向方面，主力资金净流出684.19万元，特大单买入758.08万元，占比4.67%，卖出1251.55万元， 占比7.71%；大单买入2674.80万元，占比16.49%，卖出2865.53万元，占比17.66%。 机构持仓方面，截止2025年9月30日，谱尼测试十大流通股东中，广发量化多因子混合A（005225）位 居第五大流通股东，持股266.22万股，为新进股东。香港中央结算有限公司位居第六大流通股东，持股 231.08万股，相比上期增加29.30万股。 责任编辑：小浪快报 资料显示，谱尼测试集团股份有限公司位于北京市海淀区锦带路66号院1 ...

Core Viewpoint - The company, Puni Testing, is a leading comprehensive testing and certification service provider in China, facing challenges in revenue and profitability but showing signs of improvement in recent quarters [1][6]. Group 1: Business Performance - In Q3 2025, Puni Testing reported revenue of 932 million yuan, ranking 7th among 21 companies in the industry, with the industry leader, Huace Testing, generating 4.702 billion yuan [2]. - The company's net profit for the same period was -198 million yuan, placing it 21st in the industry, while the top performer, Huace Testing, achieved a net profit of 810 million yuan [2]. - The main business segments include Life Sciences and Environmental Health (367 million yuan, 68.89%), Automotive and Other Consumer Goods (106 million yuan, 19.99%), and Safety Assurance (58.26 million yuan, 10.94%) [2]. Group 2: Financial Ratios - As of Q3 2025, Puni Testing's debt-to-asset ratio was 16.10%, lower than the previous year's 18.99% and below the industry average of 26.67%, indicating strong solvency [3]. - The gross profit margin for the same period was 29.61%, an increase from 28.24% year-on-year, but still below the industry average of 43.39%, suggesting room for improvement in profitability [3]. Group 3: Management and Shareholder Information - The chairman, Song Wei, received a salary of 872,000 yuan in 2024, a decrease of 34,800 yuan from 2023 [4]. - The number of A-share shareholders decreased by 15.81% to 21,400 as of September 30, 2025, while the average number of shares held per shareholder increased by 18.79% [5]. Group 4: Future Outlook - Longjiang Securities noted that while Puni Testing faced revenue decline and net losses in the first three quarters of 2025, the revenue decline has narrowed significantly in Q3, and the company is expected to focus on biomedicine and cosmetics to enhance laboratory capacity utilization [6]. - Revenue projections for 2025 to 2027 are 1.365 billion yuan, 1.586 billion yuan, and 1.819 billion yuan, with net profits expected to improve from -134 million yuan in 2025 to 145 million yuan in 2027 [6].

Core Viewpoint - The stock price of Puni Testing has shown a decline recently, with a year-to-date increase of only 4.32% and a significant drop over the past 60 days of 9.64% [2]. Financial Performance - For the period from January to September 2025, Puni Testing reported a revenue of 932 million yuan, representing a year-on-year decrease of 17.01%. The net profit attributable to shareholders was -199 million yuan, which is a 15.07% increase compared to the previous year [2]. - Cumulative cash dividends since the company's A-share listing amount to 336 million yuan, with 234 million yuan distributed over the past three years [3]. Shareholder Information - As of September 30, 2025, the number of shareholders for Puni Testing was 21,400, a decrease of 15.81% from the previous period. The average circulating shares per person increased by 18.79% to 16,937 shares [2]. - The top ten circulating shareholders include new entrant Guangfa Quantitative Multi-Factor Mixed A, holding 2.6622 million shares, and Hong Kong Central Clearing Limited, which increased its holdings by 293,000 shares to 2.3108 million shares [3]. Market Activity - On October 29, Puni Testing's stock price fell by 2.09%, trading at 7.97 yuan per share with a total market capitalization of 4.35 billion yuan. The net inflow of main funds was 553,600 yuan, with large single purchases accounting for 6.63% of the total [1].